Evidence map›Paper›PMID 37585886›Full record

ArticleEinstein (Sao Paulo, Brazil)2023

The use of serum alkaline phosphatase as a choledocholithiasis marker to mitigate the cost of magnetic resonance cholangiography.

Pedro Henrique Peixoto Costa, Jorge Henrique Bento de Sousa, Ian Torres de Lima, Marcos Antonio Neves Noronha, Gabriel Lunardi Aranha, Vitor Pelogi Arienzo, Phellipe Fabbrini Santos Lucas, Milton Steinman, Francisco Tustumi

Open access · diamondAbstract read
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pedro Henrique Peixoto CostaHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-7499-1378
Jorge Henrique Bento de SousaHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-6826-6823
Ian Torres de LimaHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-9673-3636
Marcos Antonio Neves NoronhaHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-2202-4164
Gabriel Lunardi AranhaHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-2875-3189
Vitor Pelogi ArienzoHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-9771-8064
Phellipe Fabbrini Santos LucasHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-3863-6085
Milton SteinmanHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-3620-5115
Francisco TustumiHospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-6695-0496
Hospital Israelita Albert Einstein · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the predictive value of preoperative serum laboratory test results for identifying choledocholithiasis and reduce the use of cholangioresonance and its inherent costs.

methodsPatients aged 21-69 years who underwent preoperative cholangioresonance examination at our institute were included. Patients with a history of fluctuating jaundice or biliary pancreatitis, bile duct dilatation on ultrasonography, and elevated levels of canalicular enzymes (alkaline phosphatase >100U/L and gamma-glutamyl transferase >50U/L) underwent cholangioresonance-guided surgery. Cases of choledocholithiasis confirmed by cholangioresonance were compared with those without choledocholithiasis. Serum laboratory data were evaluated and the diagnostic capabilities of these examinations were analyzed.

resultsA total of 104 patients were included. For detecting choledocholithiasis using alkaline phosphatase, the cut-off point was 78U/L, sensitivity was 97.6% (95%CI: 87.4-99.9), and specificity was 72.6% (95%CI: 59.8-83.1). In the binary logistic regression analysis, age (OR= 0.92; 95%CI: 0.86-0.98) and alkaline phosphatase level (OR= 1.02; 95%CI: 1.01-1.05) were selected for the final model.

conclusionSerum alkaline phosphatase levels may aid preoperative diagnosis of asymptomatic choledocholithiasis. After a global clinical assessment of the patient, serum laboratory findings may contribute to a reduction in cholangioresonance-related heathcare costs.

Indexed as

CholedocholithiasisAlkaline PhosphataseCholangiographyHumansMagnetic Resonance SpectroscopySensitivity and SpecificityUltrasonographyAlkaline Phosphatase

Identifiers

PMID37585886
PMCPMC10393214
OpenAlexW4385467920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.